Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

LD2 is an inhibitor of protein arginine methyltransferase 9 (PRMT9; IC50 = 0.9 µM).1 It reduces the proliferation of Rec-1 and Raji lymphoblasts, UPN1 mantle cell lymphoma, BL-41 Burkitt lymphoma, and OCI-Ly3 diffuse large B cell lymphoma (DLBCL) cells (IC50s = 2.5-5 µM). LD2 (2.5 µM) induces cell cycle arrest at the G2/M phase in THP-1 acute myeloid leukemia (AML) cells. It decreases phosphorylated levels of checkpoint kinase 1 (Chk1) and Chk2 in THP-1 cells. In vivo, LD2 (10 mg/kg twice per day), in combination with an anti-programmed cell death protein 1 (anti-PD-1) antibody, decreases tumor volume in an AML mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Protein arginine methyltransferase 9 inhibitors and methods of use. AS 2024/0132887 Al, (2024).